ClinicalTrials.gg
RecruitingNCT05029583Updated Jan 24, 2024

Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)

An interventional study of routine screening and physician-driven screening in Nonalcoholic Steatohepatitis and Type 2 Diabetes, sponsored by LMC Diabetes & Endocrinology Ltd.. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by LMC Diabetes & Endocrinology Ltd. · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,000
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in Non-alcoholic Fatty Liver Disease with a site in Canada — 14 open to participants now, 22 under way, 9 of them phase 3. Non-alcoholic Fatty Liver Disease · Canada.

Planned enrollment
Largest of 77
5,000 · median 164
Started
2021
with 10 others
No phase
10 of 91
4 open now
Primary completion
2025-10
later than 2 of 21 live
Registered
69th of 91
by date

Among the 91 studies in Non-alcoholic Fatty Liver Disease with a site in Canada, this one has the largest planned enrollment of the 77 interventional ones that give a count, is one of 11 that started in 2021, is one of 10 with no phase, reaches primary completion later than 2 of the 21 other live ones, and was the 69th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

14 of the 91 studies in Non-alcoholic Fatty Liver Disease with a site in Canada are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Non-alcoholic Fatty Liver Disease with a site in Canada, or all of them as a file.
02

Study summary

The study is stratified cluster randomized trial. The study population will include adults with T2D and presumed NASH.

Read the detailed description

The study is a multi-centered, stratified cluster randomized controlled, open-labeled two-phase study. Clusters will be independent LMC clinic sites with patients as participants. The use of the stratified cluster randomization design will help prevent the potential for cross-contamination of screening methods.

Study participants who meet eligibility criteria undergo NASH screening. Everything, other than routineness of screening, is maintained the same in both the groups. The screening intervention received is determined by the site of the participant's provider. All participants enrolled will undergo biochemical screening. Regardless of randomization, any participants meeting biochemical cut-offs (FIB-4 index ≥1.3 or NFS >-1.455) will undergo FibroScans. Clinical data and a health-related quality of life assessment will also be collected.

03

Conditions studied

  • Nonalcoholic Steatohepatitis
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of T2D
  • Age 18 - 80 years
  • >25 kg/m2 or waist circumference ≥102 cm in men and ≥88 cm in women

Exclusion criteria

Exclusion Criteria:

  • Known history of -proven NAFLD or NASH, , , , liver cirrhosis, hemochromatosis, drug-induced hepatitis, alcohol-related or hepatic disease, history of hepatic decompensation, solid organ transplant, or primary liver cancer, based on electronic medical record
  • History of alcohol abuse (≥30 g/day or ≥3 drinks/day for males and ≥20 g/day or ≥2 drinks/day for females)
  • Unstable patients with T2D (e.g. end stage renal disease on dialysis, late stage cancer, acute cardiovascular event or any hospitalization in the past 3 months). Note - Emergency room visit without hospitalization is not exclusionary
  • Pregnancy/lactation
  • Presence of implanted electronic medical device (i.e., pacemaker, as FibroScan cannot be performed)
  • Language barriers (i.e. inability to read the consent form translated in any of the multiple languages)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
5,000 participants (estimated)

Study arms

  • Experimental
    routine screening group

    consists of 4 clusters randomized into Group 1 (includes different clinic sites from Group 2)

    Other: routine screening

  • Active comparator
    physician-driven screening group

    consists of 4 clusters randomized into Group 2 (includes different clinic sites from Group 1)

    Other: physician-driven screening

Interventions

  • Otherroutine screening

    routine screening for advanced NASH

  • Otherphysician-driven screening

    physician-driven screening for advanced NASH

06

What researchers measure

Primary outcomes

  1. Prevalence of presumed advanced NASH based on biochemical and FibroScan results

    Percent of participants identified with presumed advanced NASH. Specific details for calculating the primary outcome of this study are blinded for health care providers, and therefore not disclosed in this description.

    Time frame: 3 months

Secondary outcomes

  1. Proportion of study participants with presumed high grade fibrosis

    Proportion of study participants with presumed any NASH (fibrosis-4 index \>2.67 or NAFLD fibrosis score \>0.675 AND FibroScan LSM ≥ 8.0 kPa)

    Time frame: 3 months

  2. Proportion of study participants with presumed any NASH

    Proportion of study participants with presumed any NASH (fibrosis-4 index ≥1.3 or NAFLD fibrosis score \>-1.455 AND FibroScan diagnosis of any stage fibrosis)

    Time frame: 3 months

  3. Proportion of study participants with presumed F2/F3 NASH

    Proportion of study participants with presumed F2/F3 NASH (fibrosis-4 index ≥1.3 or NAFLD fibrosis score \>-1.455 AND FibroScan diagnosis of F2/F3 fibrosis)

    Time frame: 3 months

  4. Proportion of study participants with a fibrosis-4 index (FIB-4) and/or NAFLD fibrosis score (NFS) above cut-off values

    Proportion of study participants with a fibrosis-4 index (FIB-4) and/or NAFLD fibrosis score (NFS) above cut-off values (FIB-4 ≥1.3 or/and NFS \>-1.455)

    Time frame: 1 day

  5. Proportion of study participants with a fibrosis and/or steatosis (stages)

    Proportion of study participants with a fibrosis and/or steatosis (stages) based on FibroScan results

    Time frame: 1 day

  6. Alcohol consumption by study arm - drinks per day

    Alcohol consumption measured as self-reported average drinks per day

    Time frame: 1 day

  7. Alcohol consumption by study arm - drinks per week

    Alcohol consumption measured as self-reported average drinks per week

    Time frame: 1 day

  8. Alcohol consumption by study arm - Alcohol Use Disorders Identification Test (AUDIT) score

    Alcohol consumption measured with the Alcohol Use Disorders Identification Test (AUDIT). AUDIT scores range from a minimum score of 0 to a maximum score of 40, with higher scores indicating a worse outcome.

    Time frame: 1 day

  9. Health-related quality of life by study arm

    Health-related quality of life determined by the chronic liver disease questionnaire for non-alcoholic steatohepatitis (CLDQ-NASH) calculated as total CLDQ-NASH score. The CLDQ-NASH instrument includes 36 items grouped into six domains: abdominal symptoms; activity/energy; emotional health; fatigue; systemic symptoms; and worry. The average of the domain scores (min: 1, max: 7) yields the total CLDQ-NASH score. The minimum possible total score is 1 and the maximum possible total score is 7, with a higher total score indicating a better outcome.

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Oct 2025, 49 months after the start.

Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 49 months is above that.

Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2021
First posted
Aug 31, 2021
StartActual
Aug 11, 2021
Primary completionEst.
Oct 5, 2025
CompletionEst.
Oct 5, 2025
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05029583
Lead sponsor
LMC Diabetes & Endocrinology Ltd.
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Aug 11, 2021
Primary completion
Oct 5, 2025 (estimated)
Completion
Oct 5, 2025 (estimated)
Last update
Jan 24, 2024

Study contacts

Lisa Chu, PhD
Contact
lisa.chu@LMC.ca
416-268-8787
Harpreet Bajaj, MD
principal investigator · LMC Diabetes & Endocrinology Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion